These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 11325840)

  • 1. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
    Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
    Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
    Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
    Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
    Emens LA; Asquith JM; Leatherman JM; Kobrin BJ; Petrik S; Laiko M; Levi J; Daphtary MM; Biedrzycki B; Wolff AC; Stearns V; Disis ML; Ye X; Piantadosi S; Fetting JH; Davidson NE; Jaffee EM
    J Clin Oncol; 2009 Dec; 27(35):5911-8. PubMed ID: 19805669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
    Ercolini AM; Ladle BH; Manning EA; Pfannenstiel LW; Armstrong TD; Machiels JP; Bieler JG; Emens LA; Reilly RT; Jaffee EM
    J Exp Med; 2005 May; 201(10):1591-602. PubMed ID: 15883172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
    Nigam A; Yacavone RF; Zahurak ML; Johns CM; Pardoll DM; Piantadosi S; Levitsky HI; Nelson WG
    Int J Oncol; 1998 Jan; 12(1):161-70. PubMed ID: 9454900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.
    Pfannenstiel LW; Lam SS; Emens LA; Jaffee EM; Armstrong TD
    Cell Immunol; 2010; 263(1):79-87. PubMed ID: 20346445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.
    Uram JN; Black CM; Flynn E; Huang L; Armstrong TD; Jaffee EM
    J Immunol; 2011 Apr; 186(7):3847-57. PubMed ID: 21346233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.
    Emens LA; Armstrong D; Biedrzycki B; Davidson N; Davis-Sproul J; Fetting J; Jaffee E; Onners B; Piantadosi S; Reilly RT; Stearns V; Tartakovsky I; Visvanathan K; Wolff A
    Hum Gene Ther; 2004 Mar; 15(3):313-37. PubMed ID: 15018740
    [No Abstract]   [Full Text] [Related]  

  • 13. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.
    Kim PS; Armstrong TD; Song H; Wolpoe ME; Weiss V; Manning EA; Huang LQ; Murata S; Sgouros G; Emens LA; Reilly RT; Jaffee EM
    J Clin Invest; 2008 May; 118(5):1700-11. PubMed ID: 18398507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
    Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy: friend or foe to cancer vaccines?
    Emens LA; Machiels JP; Reilly RT; Jaffee EM
    Curr Opin Mol Ther; 2001 Feb; 3(1):77-84. PubMed ID: 11249735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
    Disis ML; Rinn K; Knutson KL; Davis D; Caron D; dela Rosa C; Schiffman K
    Blood; 2002 Apr; 99(8):2845-50. PubMed ID: 11929774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.